Hussain M, et al. PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. ESMO Congress 2019, abstract LBA12_PR.
“Overweeg bij hypervasculaire NET met veel leverziekte adjunctieve holmium-166”
mei 2020 | Maag-darm-leveroncologie